Crossmark

Clinical implementation of endolysins targeting gram-positive bacteria points toward a combination strategy with standard-of-care antibiotics: a selective review

Crossref DOI link: https://doi.org/10.1186/s40001-025-03655-4

Published Online: 2026-01-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Vander Elst, Niels
Funding

Funding for this research was provided by:

Kronprinsessan Lovisas Förening För Barnasjukvård / Stiftelsen Axel Tielmans Minnesfond

Karolinska Institute
License Information

Text and Data Mining valid from 2026-01-09

Version of Record valid from 2026-01-27
More Information

Article History

Received: 15 September 2025

Accepted: 3 December 2025

First Online: 9 January 2026

Declarations

:

: Not applicable.

: Not applicable.

: Text editing support was provided using AI-assisted tools (ChatGPT, OpenAI) to improve clarity and language precision.

: The author declares issued and pending patent applications with regards to endolysins.

Document is current

Any future updates will be listed below